Have a feature idea you'd love to see implemented?
Let us know!
ALLO Allogene Therapeutics Inc
Price (delayed)
$2.64
Market cap
$552.05M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.64
Enterprise value
$371.1M
Allogene Therapeutics, with headquarters in South San Francisco, is a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T™) therapies for cancer. Led by
Highlights
Allogene Therapeutics's debt has plunged by 100% YoY
The EPS has grown by 35% YoY and by 10% from the previous quarter
ALLO's quick ratio is up by 33% year-on-year but it is down by 4.7% since the previous quarter
Allogene Therapeutics's equity has decreased by 17% YoY but it has increased by 12% QoQ
The gross profit has dropped by 66% year-on-year and by 51% since the previous quarter
ALLO's revenue has dropped by 66% year-on-year and by 51% since the previous quarter
Key stats
What are the main financial stats of ALLO
Market
Valuations
Earnings
Shares outstanding
209.11M
Market cap
$552.05M
Enterprise value
$371.1M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.88
Price to sales (P/S)
23,889.06
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
17,671.21
Revenue
$21,000
EBIT
-$281.93M
EBITDA
-$267.68M
Free cash flow
-$228.93M
Per share
Balance sheet
Liquidity
EPS
-$1.64
Free cash flow per share
-$1.2
Book value per share
$3.01
Revenue per share
$0
TBVPS
$3.4
Total assets
$646.88M
Total liabilities
$131.85M
Debt
$0
Equity
$515.04M
Working capital
$419.82M
Debt to equity
0
Current ratio
12.25
Quick ratio
12.19
Net debt/EBITDA
0.68
Margins
Efficiency
Dividend
EBITDA margin
-1.27M%
Gross margin
100%
Net margin
-1.34M%
Operating margin
-1.38M%
Return on assets
-43.6%
Return on equity
-54.4%
Return on invested capital
-53.2%
Return on capital employed
-46.3%
Return on sales
-1.34M%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
ALLO stock price
How has the Allogene Therapeutics stock price performed over time
Intraday
-3.65%
1 week
4.35%
1 month
6.45%
1 year
-11.11%
YTD
-17.76%
QTD
-5.71%
Financial performance
How have Allogene Therapeutics's revenue and profit performed over time
Revenue
$21,000
Gross profit
$21,000
Operating income
-$289.08M
Net income
-$281.93M
Gross margin
100%
Net margin
-1.34M%
The operating margin has dropped by 134% year-on-year and by 99% since the previous quarter
Allogene Therapeutics's net margin has plunged by 124% YoY and by 96% from the previous quarter
The gross profit has dropped by 66% year-on-year and by 51% since the previous quarter
ALLO's revenue has dropped by 66% year-on-year and by 51% since the previous quarter
Growth
What is Allogene Therapeutics's growth rate over time
Valuation
What is Allogene Therapeutics stock price valuation
P/E
N/A
P/B
0.88
P/S
23,889.06
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
17,671.21
The EPS has grown by 35% YoY and by 10% from the previous quarter
ALLO's price to book (P/B) is 66% less than its 5-year quarterly average of 2.6 and 20% less than its last 4 quarters average of 1.1
Allogene Therapeutics's equity has decreased by 17% YoY but it has increased by 12% QoQ
The stock's price to sales (P/S) is 78% more than its last 4 quarters average of 13407.7
ALLO's revenue has dropped by 66% year-on-year and by 51% since the previous quarter
Efficiency
How efficient is Allogene Therapeutics business performance
The ROS has plunged by 124% YoY and by 96% from the previous quarter
ALLO's return on invested capital is down by 5% since the previous quarter and by 3.9% year-on-year
The return on assets has increased by 3.5% year-on-year
The return on equity has increased by 2.3% year-on-year
Dividends
What is ALLO's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for ALLO.
Financial health
How did Allogene Therapeutics financials performed over time
ALLO's current ratio is up by 33% YoY but it is down by 4.3% from the previous quarter
ALLO's quick ratio is up by 33% year-on-year but it is down by 4.7% since the previous quarter
Allogene Therapeutics's debt is 100% less than its equity
The company's debt to equity has shrunk by 100% YoY
Allogene Therapeutics's debt has plunged by 100% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.